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Cerebrospinal fluid pleocytosis level as a
diagnostic predictor? A cross-sectional
study
Anne Ahrens Østergaard1, Thomas Vognbjerg Sydenham2, Mads Nybo3,4 and Åse Bengård Andersen1,4,5*
Abstract
Background: Lumbar puncture with quantification of leukocytes and differential count of cellular subsets in the
cerebrospinal fluid is a standard procedure in cases of suspected neuroinfectious conditions. However, a number of
non-infectious causes may result in a low leukocyte number (0–1000 cells/ml). We wanted to assess the diagnostic
diversity of unselected adult patients with pleocytosis in the cerebrospinal fluid.
Methods: The study is based on data from cerebrospinal fluid (CSF) analyses of all adult patients (15 years or older)
admitted to a large university hospital in Denmark during a two-year period (2008–2009). Data from the local patient
administrative system supplied with data from patient charts were combined with laboratory data.
Results: A total of 5390 cerebrospinal fluid samples from 3290 patients were included. Pleocytosis >5 leucocytes/μl
was found in samples from 262 patients of which 106 (40.5%) were caused by infection of the central nervous system
(CNS), 20 (7.6%) by infection outside CNS, 79 (30.2%) due to non-infectious neurological diseases, 23 (8.8%) by malignancy,
and 34 (13.0%) caused by other conditions. Significantly higher mean CSF leukocytes was found in patients suffering from
CNS infection (mean 1135 cells/μl, p-value <0.0001).
Conclusions: CNS infection, non-infectious neurological disease, malignancy, and infection outside CNS can cause
pleocytosis of the cerebrospinal fluid. Leukocyte counts above 100/μl is mainly caused by CNS infection, whereas the
number of differential diagnoses is higher if the CSF leukocyte counts is below 50/μl. These conditions are most commonly
caused by non-infectious neurological diseases including seizures.
Keywords: Cerebrospinal fluid, CSF, Pleocytosis, Lumbar puncture, Central nervous system infection, CNS infection, Seizures
Background
Migration of leukocytes to the cerebrospinal fluid (CSF)
is a cardinal symptom of an infectious condition affect-
ing the meninges or the cerebral parenchyma. Bacterial
and viral meningitis cannot reliably be differentiated
clinically and requires lumbar puncture to analyse the
CSF [1, 2]. Patients suffering from viral meningitis
present CSF leukocyte concentrations varying from 10
to 1000/μl, but typically below 500 [3]. In bacterial men-
ingitis CSF leukocytes vary from below 100 to more than
10,000 leukocytes/μl, often between 1000 and 5000/μl
[4]. However, pleocytosis in the CSF may also occur in
other medical conditions, e.g. neurological, rheumatic or
malignant disease [5, 6]. Some patients with pleocytosis
in the CSF never obtain a final diagnosis and in many
settings the proportion of patients with “suspected CNS
infection” is larger than that of patients with proven
aetiology [1].
Apart from the issue of a large overlap in leukocyte
concentrations caused by viral and bacterial infections,
the relative distributions of the non-infectious diagnoses
are not well described. One reason for this is the fact
that these patients are dealt with by different clinical
specialities.
Methods
This study aimed at obtaining an overview of the relative
contribution of the causes of cerebrospinal pleocytosis
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by a comprehensive method including all adult patients
(regardless indication for lumbar puncture, requesting
department, and symptomatology of the patient) admit-
ted to a large university hospital in Denmark during a
two-year period.
Pleocytosis is defined as increased cell count. In the
following the term pleocytosis will be used to describe
>5 leucocytes/μl in CSF. The study was performed at
Odense University Hospital, a large regional hospital in
Denmark with 1038 beds serving as referral hospital for
1.8 million inhabitants and holding all medical special-
ities including neurology, neurosurgery, rheumatology,
oncology and haematology.
Data from CSF analyses performed at the Department
of Clinical Biochemistry and Pharmacology from January
1st 2008 to December 31th 2009 (sample date, CSF leu-
kocytes, CSF monocytes, CSF polymorphonuclear leuko-
cytes, CSF protein, CSF glucose and plasma glucose) and
data from the patient administration system of Funen
County (FPAS; Fyns Patient Administrative System)
(patient age, sex, hospital admission dates, discharge
dates and discharge diagnoses) from 1994 to 2012 was
retrieved. In addition, we obtained data from the elec-
tronic patient records on hospital admissions and CSF
sample reports.
Only the initial CSF analysis requested with pleocytosis
(>5 leukocytes/μl after correction for erythrocytes (1
leucocyte/1000 erythrocytes)) in hospitalized patients at
age of 15 years or older were included. Exclusion criteria
were: not the first CSF sample in the time period, wrong
social security number, if the sample was not cerebro-
spinal fluid, if the erythrocytes were in layers or too
numerous to quantify, if a sample was collected by a
method different from lumbar puncture, or if the patient
was transferred to another hospital with an uncertain
diagnosis. If a sample was analysed more than once, the
report given to the clinician was used (Fig. 1). Discharge
diagnoses (ICD-10) were used to categorise the cause of
pleocytosis. However, the cause of pleocytosis was ad-
justed in the following circumstances: 1) Discharge
diagnosis was not verified para-clinically (magnetic
resonance imaging (MRI)/computed tomography (CT),
microbiological analyses, flow-cytometry, or autopsy)
and the discharge summary mentioned a diagnosis in
plain text not coded as a discharge diagnosis; the cause
of pleocytosis was changed to this diagnosis. 2) a CNS
infection was mentioned in the discharge summary but
not included as a discharge diagnosis; Cause of pleocyto-
sis was changed to CNS infection. 3) a discharge diagno-
sis was not verified nor was CNS infection but a
secondary diagnosis was verified; the cause of pleocytosis
was changed to this diagnosis. 4) Discharge diagnosis
was “Observation for other suspected diseases and con-
ditions” or “Observation for suspected nervous system
disorder” and the suspected disorder was CNS infection;
the cause of pleocytosis was changed to CNS infection,
5) the patient received full treatment for a CNS infection
but this was not included in discharge summary; the
cause of pleocytosis was changed to CNS infection. 6)
the discharge diagnosis did not coincide with the pa-
tient chart or discharge summary; the cause of pleo-
cytosis was changed to the cause mentioned in the
chart. 7) a clear diagnosis was not made at time of
discharge but was verified within 3 months after
discharge date; this diagnosis was used as cause of
pleocytosis.
The category CNS infection was further divided into 2
groups: verified and probable. A discharge diagnosis was
considered verified if the diagnosis was verified by MRI,
CT, microbiological analyses, or autopsy.
Fig. 1 Flowchart of study inclusion
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Charlson index score [7] was used to describe patients
comorbidity. Charlson score estimating risk of death
from comorbid disease in longitudinal studies by scoring
each comorbid disease a score of 1, 2, 3, or 6.22 comor-
bidity conditions are included. Calculation was based on
registered diagnoses in the patient administration system
from years 1994 to 2009.
Statistical analysis
Data processing was performed in STATA version 13.1–
14.0. Wilcoxon/Mann-Whitney (Mann-Whitney U/
Wilcoxon rank sum) test was performed for data not
normally distributed (sex, Charlson score, CSF leuko-
cytes, CSF protein, CSF monocyte proportion, and
CSF polymorph nuclear leukocyte proportion). Student’s
t-test was used if data was normally distributed (age). All
p-values were comparisons between the marked category
and the other categories. Only significant p-values (≤0.05)
were included.
Results
Out of 5390 unselected cerebrospinal fluid samples, 262
met the inclusion criteria (Fig. 1). The neurological de-
partment (56.5%), department of emergency admission
(14.9%), and the department of intensive care (7.3%)
were the main contributors to CSF analyses.
Patients were divided into diagnosis categories of CNS
infection, Infection outside CNS, Non-infectious neuro-
logical diseases, Malignancy, Other, and subgroups
(Appendix A). CNS infection amounted to 40.5% of the
causes of pleocytosis. Infection outside CNS to 7.6%,
Non-infectious neurological diseases to 30.2%, Malignancy
8.8%, and Other 13.0%.
There was no significant difference in distribution of
sex in any of the categories (Table 1). Significantly lower
mean age was found in the Non-infectious neurological
diseases category (mean age 46.1, p-value 0.0088). Mean
Charlson score in the 262 patients was 0.9, range 0–11.
Mean Charlson score was significantly lower in the
Non-infectious neurological diseases category (mean 0.6,
p-value 0.0125), while it was significantly higher in the
Malignancy (mean 2.7, p-value <0.001) than in all other
categories. In general, there was a tendency of high
mean Charlson score in the categories with high
mean age.
In 141 patients mean CSF/plasma glucose ratio was
0.6 (normal). Significantly lower CSF/plasma glucose
ratio was found in the decreased interval (<0.46) for
CNS infection (mean 0.2, p 0.0085). Significant higher
Table 1 Summery of baseline findings by diagnosis category
Diagnosis category
CNS infection
(n = 106)
Infection outside CNS
(n = 20)
Non-infectious neurological
diseases (n = 79)
Malignancy, all foci
(n = 23)
Other (n = 34) Total (n = 262)
Sexa n (%) n (%) n (%) n (%) n (%) n (%)
Male 49 (46.2) 11 (55.0) 43 (54.4) 14 (60.9) 16 (47.1) 133 (50.8)
Female 57 (53.8) 9 (45.0) 36 (45.6) 9 (39.1) 18 (52.9) 129 (49.2)
Ageb n (%) n (%) n (%) n (%) n (%) n (%)
< 36 yrs 26 (24.5) 5 (25.0) 24 (30.6) 2 (8.7) 7 (20.6) 64 (24.4)
36-51 yrs 31 (29.3) 27 (34.2) 6 (26.1)* 7 (20.6) 71 (27.1)
52-64 yrs 20 (18.9) 4 (20.0) 14 (17.7) 9 (39.1) 13 (38.2) 60 (22.9)
≥ 65 yrs 29 (27.4) 11 (55.0) 14 (17.7) 6 (26.1) 7 (20.6) 67 (25.6)
Mean 50.4 58.5 46.1* 59.1 52.0 50.7
Range 15–88 17–91 20–89 28–81 17–95 15–95
Charlson scorea n (%) n (%) n (%) n (%) n (%) n (%)
0 66 (62.3) 9 (45.0) 52 (65.8) 1 (4.4) 19 (55.9) 147 (56.1)
1 25 (23.6) 3 (15.0) 18 (22.8) 1 (4.4) 9 (26.5) 56 (21.4)
2 7 (6.6) 5 (25.0) 5 (6.3) 14 (60.9) 6 (17.7) 37 (14.1)
3 2 (1.9) 2 (10.0) 2 (2.5) 3 (13.0) 9 (3.4)
≥4 6 (5.7) 1 (5.0) 2 (2.5) 4 (17.4) 13 (5.0)
Mean 0.7 1.2 0.6 2.7** 0.6 0.9
Range 0–6 0–4 0–7 0–11 0–2 0–11
aWilcoxon-Mann-Whitney test
bp-values calculated by Student’s t-test
*p-value <0.01
**p-value <0.001
Østergaard et al. BMC Clinical Pathology  (2017) 17:15 Page 3 of 8
CSF/plasma glucose ratio was found in the decreased
interval (<0.46) for Non-infectious neurological dis-
eases (mean 0.4, p 0.0276).
The mean concentration of CSF leukocytes was 494/μl
(Table 2). Significantly higher concentrations of mean
CSF leukocytes were found in patients with CNS infec-
tion (mean 1135, p-value <0.001). In the category CNS
infection no distinction between viral and bacterial neu-
roinfection was made. When only verified diagnoses
were included, a higher concentration of CSF leukocytes
were found in the category Meningitis, acute bacterial
(p-value = 0.0002) (Table 5) compared to the others in
CNS infection.
The proportion of patients in the CNS infection cat-
egory increased with increasing CSF leukocyte concen-
tration, and at leukocyte counts above 100/μl CNS
infection was the most frequent cause of pleocytosis
(Fig. 2). Eighty seven point three percent of the pa-
tients with more than 200 leukocytes were diagnosed
with CNS infection.
In CSF samples with leukocytes below 50/μl especially
non-infectious neurological diagnoses should be consid-
ered as differential diagnoses, since the proportion of
CNS infection increased with increasing CSF leukocytes
(Fig. 3). The category of Other seemed to occur mainly
in patients with CSF leukocytes below 100/μl. Infection
outside CNS occurred primarily when CSF leukocytes
were below 50/μl. CNS infection was the only category
present in all intervals.
The mean CSF protein concentration in all patients
was 1.0 g/l (Table 2). CSF protein was normal (0.2–
0.4 g/l) or decreased in 32.4% of all patients. All patients
with CNS infection had a significantly higher level of
protein in CSF (mean 1.4) (p-value <0.0001). CNS pro-
tein is known to be increased in meningitis, but also to
be one of the least specific parameters in CSF [4].
Of the 106 patients with CNS infection 59 (55.7%)
were paraclinically confirmed. For the categories of
malignancy 20 (87.0%), other 15 (44.1%), non-infectious
neurologically disease 37 (46.8%), and other infection 10
(50.0%) were paraclinically confirmed. Table 3 shows
that more diagnoses in the CNS infection category were
paraclinically verified as cell count increases. Mean pro-
tein level was higher in the verified CNS infections than
in probable CNS infection. CSF/plasma glucose ratios
shows a tendency of being lower in total in the verified
category and are in both groups the lowest when cell
count is high.
For six patients, seizures, epilepsy or status epilepticus
was the cause of pleocytosis. Two patients had <10
Table 2 Summary of CSF findings by diagnosis category
Diagnosis category
CNS infection
(n = 106)
Infection outside
CNS (n = 20)
Non-infectious
neurological
diseases (n = 79)
Malignancy, all
foci (n = 23)
Other (n = 34) Total (n = 262)
CSF leukocytes/μla n (%) [mean] n (%) [mean] n (%) [mean] n (%) [mean] n (%) [mean] n (%) [mean]
6–10 11 (10.4) 8.1 10 (50.0) 7.3 32 (40.5) 7.3 8 (34.8) 7.4 14 (41.2) 7.2 75 (28.6) 7.4
>10–50 23 (21.7) 29.3 9 (45.0) 22.9 34 (43.0) 20.2 11 (47.8) 21.9 14 (41.2) 20.1 91 (34.7) 23.0
>50–100 8 (7.6) 84.0 3 (3.8) 66 2 (8.7) 62.5 5 (14.7) 69.8 18 (6.9) 74.7
>100–200 17 (16.0) 135.0 6 (7.6) 138 1 (2.9) 159 24 (9.2) 136.8
>200–400 13 (12.3) 266.4 1 (5.0) 221 2 (2.5) 247.5 1 (4.4) 347 17 (6.5) 266.2
>400–600 12 (11.3) 524.6 1 (1.3) 537 13 (5.0) 525.5
>600–800 2 (1.9) 744 2 (0.8) 744
>800–1000 3 (2.8) 896 3 (1.2) 896
>1000 17 (16.0) 6041.2 1 (1.3) 2015 1 (4.4) 1980 19 (7.3) 5615.5
Total 106 (100.0) 1135.5** 20 (100.0) 25.0* 79 (100.0) 63.2** 23 (100.0) 119.7 34 (100.0) 26.2* 262 (100.0) 494.3
CSF protein g/la n (%) [mean] n (%) [mean] n (%) [mean] n (%) [mean] n (%) [mean] n (%) [mean]
<0.2 1 (1.3) 0.0 1 (2.9) 0.0 2 (0.8) 0.0
0.2–0.4 18 (17.0) 0.4 12 (60.0) 0.3 34 (43.0) 0.3 8 (34.8) 0.3 11 (32.4) 0.4 83 (31.7) 0.3
0.41–1.11 50 (47.2) 0.7 8 (40.0) 0.8 36 (45.6) 0.7 10 (43.5) 0.6 18 (52.9) 0.6 122 (46.6) 0.7
>1.11 38 (35.9) 2.8 8 (10.1) 2.5 5 (21.7) 2.9 4 (11.8) 2.6 55 (21.0) 2.8
Total 106 (100.0) 1.4** 20 (100.0) 0.5 79 (100.0) 0.7** 23 (100.0) 1.0 34 (100.0) 0.7 262 (100.0) 1.0
aWilcoxon-Mann-Whitney test
bp-values by Student’s t-test
*p-value <0.01
**p-value <0.001
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leukocytes/μl and four patiens had 10–50 leukocytes/μl
(Table 4). Pleocytosis has previosly been found in
patientes after seizures [8]. Higher concentrations of
CSF leukocytes were found in Other neurological dis-
eases. One patient, who suffered from obstructive hydro-
cephalus, had >1000 leukocytes/μl in CSF (categorised
as Other neurological diseases) but did not suffer from
neuroinfection. No distinction between viral and bacter-
ial meningitis was made. No patients had tuberculosis or
fungal CNS infection as shown in the Appendix.
Discussion
The discharge diagnoses were retrospectively adjusted
for 36 (13.7%) patients following discharge summary and
patient chart review. We found it important to manually
review the charts as also suggested by others in retro-
spective studies to secure that all relevant diagnoses
were included [9, 10].
A wide span of diagnoses were included in the Others
category including neurosarcoidosis and rheumatic dis-
eases, which are known causes of pleocytosis [6, 11–13].
In the category Other, the mean CSF leukocyte concen-
tration was 26/μl (SD 32.6). The patients in this category
did not differ from the other patients in age, sex, or
Charlson score. It could be speculated that some of
these patients suffered from a benign viral infection
either not detected by available diagnostic setups or
not tested for.
Fig. 2 Distribution of diagnose category per cell count. CNS infection is the only category present in all intervals. The category of Other occurs mainly
in patients with CSF leukocytes below 100/μl. Infection outside CNS occurs primarily when CSF leukocytes were below 50/μl
Fig. 3 Distribution of diagnose category as a percentage per cell count. The proportion of patients in the CNS infection category increased with
increasing CSF leukocyte concentration, and at leukocyte counts above 100/μl CNS infection was the most frequent cause of pleocytosis
Østergaard et al. BMC Clinical Pathology  (2017) 17:15 Page 5 of 8
In the Non-infectious neurological diseases category
five patients suffered from Migraine or Headache and
three patients from Paralysis/paresis of facial nerve.
These eight patients could have suffered from a mild
viral CNS infection or Lyme’s disease, since viral CNS
infection can present with similar symptoms [14, 15].
However, variation from the normal levels cannot be
ruled out.
Three patients in the Malignancy category suffered
from lung or oropharyngeal cancer. Previously, it has
been found that patients can develop chemical meningi-
tis (sterile and inflammatory) due to concurrent systemic
and local chemotherapy [16]. This could explain pleocy-
tosis in these patients. One patient in the Malignancy
category was found with 1980 cells in CSF and suffered
from agranulocytosis secondary to cancer chemotherapy
but was not found to suffer from a CNS infection
though the high cell count would suggest otherwise.
Neither was the patient found to suffer from infection
else where and was therefore categorized as Malignancy.
This explains the high mean cell count in the subgroup
Cancer, foci elsewhere (Table 5).
Limitations
The study was performed retrospectively, which means
that no actions of the treating staff or patients could in-
fluence the results. A limitation of the study is the fact
that data only was available from registers and patient
charts, which might have led to incorrect categorization
of some of the patients. However, all patients charts have
been reviewed and categorized as part of this study as
described in the methods section. Not all diagnoses were
paraclinically confirmed. This could be due to adminis-
tration of antimicrobial therapy prior to lumbar punc-
ture or due to insufficient sensitivity of the available
methods.
Conclusions
This study correlates CSF findings to final diagnosis.
CNS infection, non-infectious neurological disease,
Table 3 CSF leukocyte count, mean protein and mean CSF/plasma glucose ratio in verified and probable CNS infection
CSF leukocytes
/μl a
CNS infection, Verified CNS infection, Probable Total
n (% horizontal) Protein g/l
Mean (range)
Glucose ratio
mean (range)
n (% horizontal) Protein g/l
mean (range)
Glucose ratio
mean (range)
n (% vertical) Protein g/l
mean (range)
Glucose ratio
mean (range)
6–10 4 (36.4) 0.6 (0.4–0.9) - 7 (63.6) 0.7 (0.4–0.9) 0.7 (0.5–0.9) 11 (10.4) 0,6 (0.4–0.9) 0.7 (0.5–0.9)
>10–50 9 (39.1) 0.9 (0.3–2.2) 0,5 (0.4–0.7) 14 (60.9) 0.6 (0.3–2.2) 0.6 (0.3–1.0) 23 (21.7) 0.7 (0.2–2.2) 0.6 (0.3–1.0)
>50–100 5 (62.5) 1.0 (0.2–1.6) 0.6 (0.5–0.7) 3 (37.5) 0.6 (0.4–0.7) 0.4 (0.4–0.5) 8 (7.6) 0,8 (0.2–1.6) 0.5 (0.4–0.7)
>100–200 7 (41.2) 0.8 (0.3–1.3) 0.7 (0.5–0.7) 10 (58.8) 0.8 (0.4–1.7) 0.6 (0.6–0.8) 17 (16.0) 0.8 (0.3–1.7) 0.7 (0.6–1.0)
>200–400 8 (61.5) 1.3 (0.4–2.4) 0.5 (0.4–0.6) 5 (38.5) 0.9 (0.5–1.9) 0.6 (0.5–0.8) 13 (12.3) 1.1 (0.4–2.4) 0.6 (0.4–0.8)
>400–600 8 (66.7) 2.3 (0.7–6.8) 0.4 (0.0–0.6) 4 (33.3) 1.3 (0.6–2.8) 0.6 (0.4–0.9) 12 (11.3) 2.0 (0.6–6.8) 0.5 (0.0–0.9)
>600–800 2 (100.0) 1.4 (0.8–2) 0.5 (0.3–0.6) 2 (1.9) 1.4 (0.8–2.0) 0.5 (0.3–0.6)
>800–1000 2 (66.7) 1.2 (1.2–1.2) 0.7 (0.7–0.7) 1 (33.3) 1.4 0.4 3 (2.8) 1.3 (1.2–1.4) 0.5 (0.4–0.7)
>1000 14 (82.4) 4 (0.8–6.8) 0.1 (0.1–0.1) 3 (17.6) 4.4 (1.5–9.0) 0.2 (0.1–0.1) 17 (16.0) 3.6 (0.8–6.8) 0.2 (0.0–0.4)
Total 59 (55.7) 1.8 (0.2–6.8) 0.4 (0.0–1.0) 47 (44.3) 1.0 (0.2–9.0) 0.6 (0.1–1.0) 106 (100.0) 1.4 (0.2–9) 0.5 (0.0–1.0)
- missing data: CSV/plasma glucose ratio only available in 59 of 106 patients
Table 4 CSF leukocyte count in non-infectious neurological diseases subgroups
Non-infectious neurological diseases
subgroup
CSF leukocytes/μl
≤10 >10–50 >50–100 >100–200 >200–400 >400–600 >600 Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Encephalitis/myelitis, non-infectious 8 (66.7) 2 (16.7) 1 (8.3) 1 (8.3) 12 (100.0)
Seizures/epilepsy/status epilepticus 2 (33.3) 4 (66.7) 6 (100.0)
Ischemia/infarction/stroke 4 (36.3) 4 (36.6) 1 (9.1) 2 (18.2) 11 (100.0)
Intracranial haemorrhage 1 (50.0) 1 (50.0) 2 (100.0)
Multiple sclerosis 8 (53.3) 7 (46.7) 15 (100.0)
Demyelinating disease/polyneuropathy 2 (40.0) 3 (60.0) 5 (100.0)
Paralysis/palsy of cranial nerve 2 (66.7) 1 (33.3) 3 (100.0)
Headache/migraine 3 (60.0) 2 (40.0) 5 (100.0)
Other neurological 11 (55.0) 5 (25.0) 1 (5.0) 1 (5.0) 1 (5.0) 1 (5.0) 20 (100.0)
Total 32 (40.5) 34 (43.0) 3 (3.8) 6 (7.6) 2 (2.5) 1 (1.3) 1 (1.3) 79 (100.0)
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malignancy, and infection outside CNS can cause
pleocytosis of the cerebrospinal fluid. Leukocyte
counts above 100/μl are mainly caused by CNS in-
fection, whereas the number of differential diagnoses
is higher when CSF leukocytes levels are below 50/μl.
These conditions are most commonly caused by non-
infectious neurological diseases including seizures.
Appendix
Abbreviations
CNS: Central nervous system; CSF: Cerebrospinal fluid; CT: Computed tomography;
MRI: Magnetic resonance imaging; PCR: Polymerace chain reaction
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Table 5 Summary of subgroups in the diagnosis categories
Number Percent Mean CSF
leukocytes/μl
CNS infection 106 40.5 1135.5
Meningitis. viral/unknown agent 38 35.9 617.0
Meningitis. acute bacterial 21 19.8 3591.3
Meningitis. borrelia/syphilis 25 23.6 150.6
Encephalitis. infectious 11 10.4 295.3
CNS abscess 3 2.8 4654.3
Other CNS infection
(Including: Herpes zoster with
other complication in CNS,
Hydrocephalus caused by
infectious or parasitic disease
classified elsewhere,
Meningoencephalitis due to
toxoplasmosis, Polyneuropathy
caused by infectious or parasitic
disease classified elsewhere,
Viral infection of CNS unspecified)
8 7.6 66.0
Infection outside CNS 20 7.6 25.0
Endocarditis 2 9.5 113.5
Sepsis 10 47.6 18.8
Other infection with foci outside CNS
(including: Acute pharyngitis,
Acute sinusitis, Analabsces, Other
pneumonia due to other unspecified
microorganism, Oral candidiasis,
HIV with other infectious and parasitic
disease, Erysiphelas, unspecified,
Viralinfection, unspecified, Pilonidal
cyst with abscess)
8 40.0 10.6
Non-infectious neurological diseases 79 30.2 63.2
Encephalitis/myelitis. Non-infectious 12 15.2 108.3
Seizures/epilepsy/status epilepticus 6 7.6 15.8
Ischemia/infarction/stroke 11 13.9 38.9
Intracranial haemorrhage 2 2.5 85.0
Multiple sclerosis 15 19.0 15.0
Demyelinating disease/
polyneuropathy
5 6.3 10.8
Paralysis/palsy of cranial nerve 3 3.8 29.7
Headache/migraine 5 6.3 10.2
Other neurological 20 25.3 129.1
Table 5 Summary of subgroups in the diagnosis categories
(Continued)
(including: Acute transverse myelitis
in demyelinating disease of central
nervous system, Other extrapyramidal
and movement disorders, Ventriculitis
of the brain, unspecified, Sequelae of
inflammatory diseases of central
nervous system), Obstructive
hydrocephalus, Spinal stenosis,
Herniation of lumbar disc with
radiculopathy, Disorder of central
nervous system, unspecified, Symptom
of central nervous system unspecified)
Malignancy. all foci 23 8.8 119.7
Lymphoma 9 39.13 20.7
Leukaemia 3 13.04 16.3
CNS cancer 5 21.74 30.6
Cancer. foci elsewhere
(Including: Malignant neoplasm
of unspecified part of unspecified
bronchus or lung, Malignant
neoplasm of oropharynx, unspecified,
Agranulocytosis secondary to cancer
chemotherapy)
4 17.39 500.5
Carcinomatosis 2 8.7 181.0
Other 34 13.0 26.2
Sarcoidosis 4 11.4 54.5
Rheumatologic 2 5.7 89.0
Cardiologic. non-infectious 2 5.7 8.0
Observation for suspected/other
or not specified findings
8 22.9 25.9
Others
(Including: Acute respiratory failure,
Fever, unspecified, Hypokalemia,
Complications following infusion,
transfusion and therapeutic injection,
Care involving use of rehabilitation
procedure, unspecified, Unspecified
multiple injuries, Hypopituitarism,
Benign paroxysmal vertigo)
18 52.9 15.1
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